Literature DB >> 3758148

Protein binding of tolfenamic acid in the plasma from patients with renal and hepatic disease.

M Láznícek, K E Senius.   

Abstract

The protein binding of tolfenamic acid in plasma from patients with renal and hepatic disorders was studied by equilibrium dialysis. Drug binding to the cellular components of whole blood and blood cell suspensions was also measured. Salicylic acid was used as the reference drug in all experiments. Renal and hepatic diseases increased the unbound fraction of tolfenamic acid. Free drug fractions were significantly correlated with changes in creatinine, urea, and total bilirubin, but not with those in albumin or total protein in plasma. Comparison of the theoretical binding parameters in control plasma and similar changes in protein binding in all the plasma samples studied revealed that tolfenamic acid and salicylic acid probably share a common primary binding site. The significance of the correlation permits use of salicylic acid as a model drug for predicting changes in the protein binding of tolfenamic acid. The measurements of binding properties in whole blood and blood cell--buffer suspension showed that tolfenamic acid interacts with the lipid membrane structures of blood cells, while salicylic acid is distributed into the aqueous cell space.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3758148     DOI: 10.1007/bf00542420

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  30 in total

1.  Further characterization of specific drug binding sites on human serum albumin.

Authors:  G Sudlow; D J Birkett; D N Wade
Journal:  Mol Pharmacol       Date:  1976-11       Impact factor: 4.436

2.  The protein binding of some drugs in plasma from patients with alcoholic liver disease.

Authors:  M Affrime; M M Reidenberg
Journal:  Eur J Clin Pharmacol       Date:  1975-04-04       Impact factor: 2.953

3.  Protein binding of salicylate in uremic and normal plasma.

Authors:  O Borgå; I O Cederlöf; V A Ringberger; A Norlin
Journal:  Clin Pharmacol Ther       Date:  1976-10       Impact factor: 6.875

Review 4.  Effect of disease states on plasma protein binding of drugs.

Authors:  M M Reidenberg
Journal:  Med Clin North Am       Date:  1974-09       Impact factor: 5.456

5.  Pentazocine binding to blood cells and plasma proteins.

Authors:  M Ehrnebo; S Agurell; L O Boréus; E Gordon; U Lönroth
Journal:  Clin Pharmacol Ther       Date:  1974-09       Impact factor: 6.875

Review 6.  Drug pharmacokinetics in cardiac and hepatic disease.

Authors:  R L Williams; L Z Benet
Journal:  Annu Rev Pharmacol Toxicol       Date:  1980       Impact factor: 13.820

7.  Inhibition of prostaglandin biosynthesis by tolfenamic acid in vitro.

Authors:  I B Lindén; J Parantainen; H Vapaatalo
Journal:  Scand J Rheumatol       Date:  1976       Impact factor: 3.641

8.  Theoretical analysis of the binding of salicylate by human serum albumin: the relationship between free and bound drug and therapeutic levels.

Authors:  W D Wosilait
Journal:  Eur J Clin Pharmacol       Date:  1976-02-06       Impact factor: 2.953

9.  Prostaglandin biosynthesis inhibitors and endometriosis.

Authors:  A Kauppila; J Puolakka; O Ylikorkala
Journal:  Prostaglandins       Date:  1979-10

10.  Plasma protein carbamylation and decreased acidic drug protein binding in uremia.

Authors:  S Erill; R Calvo; R Carlos
Journal:  Clin Pharmacol Ther       Date:  1980-05       Impact factor: 6.875

View more
  3 in total

Review 1.  Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

Authors:  R Zini; P Riant; J Barré; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

2.  Distribution and elimination characteristics of 111In-DTPA-D-phe1-octreotide and 111In-DTPA-L-phe1-octreotide in rats.

Authors:  Alice Laznickova; M Laznicek; F Trejtnar; L Melicharova; Kazuko Horiuchi Suzuki; Hiromichi Akizawa; Yasushi Arano; Akira Yokoyama
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2002 Jan-Mar       Impact factor: 2.441

3.  Kidney and liver contributions to salicylate metabolism in rats.

Authors:  M Láznícek; A Láznícková
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1994 Jan-Mar       Impact factor: 2.441

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.